On September 10, 2026, Arcadia Biosciences, Inc. (RKDA) held its 2026 Annual Meeting of Stockholders. At this meeting, the company’s stockholders approved the 2026 Omnibus Equity Incentive Plan (the “2026 Plan”). The plan was previously approved by the company’s Board of Directors and became effective immediately upon stockholder approval.
The 2026 Plan serves as the successor to the company’s 2015 Omnibus Equity Incentive Plan, which expired and terminated in 2025. The 2015 Plan will continue to govern awards that were previously granted under it. A detailed description of the 2026 Plan is included in Proposal 3 of the company’s definitive Proxy Statement on Schedule 14A filed with the SEC on August 10, 2026. The full text of the 2026 Plan is filed as Exhibit 10.1 to this current report.
The meeting also addressed several other matters, including the election of directors and advisory votes on executive compensation. Stockholders voted on a proposal to approve an amendment to the company’s certificate of incorporation to effect a reverse stock split, if the Board determines to do so before June 30, 2027, at a ratio ranging from 1-for-2 to 1-for-10.
